purinostat mesylate + pomalidomide + dexamethasone

purinostat mesylate + pomalidomide + dexamethasone is an investigational combination therapy under clinical development for patients with relapsed or refractory multiple myeloma. Purinostat mesylate is a highly selective class I/IIb histone deacetylase (HDAC) inhibitor with demonstrated antitumor activity in multiple myeloma and lymphoma models, outperforming existing pan-HDAC inhibitors. Pomalidomide is an immunomodulatory agent that promotes anti-tumor immunity and direct cancer cell cytotoxicity, while dexamethasone is a synthetic glucocorticoid with cytotoxic and anti-inflammatory effects. Combined, these agents target tumor cell survival mechanisms and remodel the tumor microenvironment, showing synergistic efficacy and enhanced immune activation in preclinical and early clinical studies for relapsed or refractory multiple myeloma.